Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.

Many recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recen...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Smith, C, Mirza, F, Pasquetto, V, Tscharke, D, Palmowski, M, Dunbar, P, Sette, A, Harris, A, Cerundolo, V
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2005

Gelijkaardige items

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
door: Smith, C, et al.
Gepubliceerd in: (2005)

Immunodomination during peripheral vaccinia virus infection.
door: Leon C W Lin, et al.
Gepubliceerd in: (2013-01-01)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
door: Sharpe, S, et al.
Gepubliceerd in: (2003)

Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
door: Gileadi, U, et al.
Gepubliceerd in: (1999)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
door: Caroline Staib, et al.
Gepubliceerd in: (2003-04-01)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
door: Dorrell, L, et al.
Gepubliceerd in: (2000)

Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
door: Valmori, D, et al.
Gepubliceerd in: (2000)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
door: Alharbi, N
Gepubliceerd in: (2014)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
door: McConkey, S, et al.
Gepubliceerd in: (2003)

Clinical development of Modified Vaccinia virus Ankara vaccines.
door: Gilbert, S
Gepubliceerd in: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
door: Gilbert, S
Gepubliceerd in: (2013)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
door: Rosario, M, et al.
Gepubliceerd in: (2010)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
door: Hanke, T, et al.
Gepubliceerd in: (1998)

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
door: Allen, T, et al.
Gepubliceerd in: (2000)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
door: Matthew G Cottingham, et al.
Gepubliceerd in: (2008-02-01)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
door: Behboudi, S, et al.
Gepubliceerd in: (2004)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
door: Cottingham, M, et al.
Gepubliceerd in: (2008)

Selection of Vaccinia Virus Recombinants Using CRISPR/Cas9
door: Anjali Gowripalan, et al.
Gepubliceerd in: (2021-12-01)

Poxviral Ankyrin Proteins
door: Michael H. Herbert, et al.
Gepubliceerd in: (2015-02-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
door: Matthew G. Cottingham, et al.
Gepubliceerd in: (2011-01-01)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
door: Ansar A Pathan, et al.
Gepubliceerd in: (2007-10-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
door: C. Staib, et al.
Gepubliceerd in: (2000-06-01)

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
door: Sharpe, S, et al.
Gepubliceerd in: (2001)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
door: Olga Vladimirovna Orlova, et al.
Gepubliceerd in: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
door: Volker Sandig, et al.
Gepubliceerd in: (2013-11-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
Gepubliceerd in: (2011-01-01)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
door: Pathan, A, et al.
Gepubliceerd in: (2007)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials.
door: Ansar A. Pathan, et al.
Gepubliceerd in: (2011-01-01)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
door: Pathan, A, et al.
Gepubliceerd in: (2007)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
door: M. F. Ferrer, et al.
Gepubliceerd in: (2007-09-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
door: Moorthy, V, et al.
Gepubliceerd in: (2003)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
door: Flavia Chiuppesi, et al.
Gepubliceerd in: (2024-02-01)

Methods of treating Poxviral Infections
door: Ramstedt, U, et al.
Gepubliceerd in: (2011)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
door: McShane, H, et al.
Gepubliceerd in: (2004)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
door: Rachael Chiam, et al.
Gepubliceerd in: (2009-06-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
door: Mingwang Shen, et al.
Gepubliceerd in: (2024-10-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
door: Kaïdre Bendjama, et al.
Gepubliceerd in: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
door: Malachy I. Okeke, et al.
Gepubliceerd in: (2017-10-01)

Nodular Dermatitis: Emergence of Novel Poxviral Infection in Russia
door: S. V. Borisevich, et al.
Gepubliceerd in: (2018-04-01)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
door: Webster, D, et al.
Gepubliceerd in: (2005)